Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

NASDAQ REGN

$374.26 0.00 (0.00)%

High N/A Low N/A Volume 6,696 Market Cap 39.72B
08/17/18 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Financial information

NEWSROOM

  • Aug 17

    FDA Approves EYLEA® (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration

    Read on
  • Aug 16

    Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

    Read on

EVENTS

  • Regeneron Pharmaceuticals Q2 2018 Earnings Conference Call
    Aug 2, 2018

  • ASRS 2018
    Jul 24, 2018

Events & Presentations

NASDAQ REGN

$374.26 0.00 (0.00)%

High N/A Low N/A Volume 6,696 Market Cap 39.72B
08/17/18 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Stock information

Financial information